Key result
Late OAC discontinuation post-AF ablation is linked to ~39% lower net adverse events.
Why the study?
Does oral anticoagulant discontinuation beyond 1 year after successful catheter ablation reduce the composite of stroke or systemic embolism and major bleeding in atrial fibrillation patients with CHA2DS2-VA scores >=2?
Cohort (n=3,637)
Yes
Does oral anticoagulant discontinuation beyond 1 year after successful catheter ablation reduce the composite of stroke or systemic embolism and major bleeding in atrial fibrillation patients with CHA2DS2-VA scores >=2?
In a nationwide Korean cohort, discontinuing oral anticoagulation 1 year after recurrence-free AF ablation was associated with lower major bleeding without increased thromboembolic risk in patients with CHA2DS2-VA scores of 2 to 4.
Answers are grounded in this paper and cite their sources.
May support individualized OAC decisions post-ablation in moderate-risk patients; leaves open randomized confirmation before practice change.
Oral anticoagulant (OAC) discontinuation after atrial fibrillation (AF) ablation may be feasible in selected patients; however, outcomes in those at high stroke risk remain unclear. This study aimed to evaluate associations between OAC discontinuation beyond 1 year after ablation and thromboembolic or bleeding events across CHA2DS2-VA risk strata. Patients without AF recurrence within 12 months of catheter ablation and with CHA2DS2-VA scores ≥2 were identified from the Korean National Health Insurance Service database and classified as OAC continuers or discontinuers based on prescription coverage at the 12-month landmark. The primary outcome was a composite of stroke or systemic embolism and major bleeding. Doubly robust estimation combined overlap weighting with covariate-adjusted Cox regression, stratified by CHA2DS2-VA score (2-4 and ≥5). Among 3,637 patients (mean age: 60.8 ± 9.7 years, 27.1% female, mean CHA2DS2-VA 3.2 ± 1.3), discontinuation in those with scores of 2-4 (n = 3,054) was associated with lower risks of the composite event (HR: 0.61; 95% CI: 0.38-0.96) and major bleeding (HR: 0.51; 95% CI: 0.29-0.90), without increased stroke or systemic embolism (HR: 0.73; 95% CI: 0.34-1.58). In those with scores ≥5 (n = 583), discontinuation was not significantly associated with any outcome, and tests for interaction were not significant (all P > 0.46). In this nationwide cohort, OAC discontinuation beyond 1 year after AF ablation was associated with decreased bleeding risk without a corresponding increase in thromboembolic events among patients with CHA2DS2-VA score 2 to 4.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) conducted a cohort in Atrial fibrillation without recurrence 12 months after catheter ablation and CHA2DS2-VA score >=2 (n=3,637). Oral anticoagulant (OAC) discontinuation beyond 1 year after catheter ablation vs. Oral anticoagulant (OAC) continuation beyond 1 year after catheter ablation was evaluated on Composite of stroke or systemic embolism and major bleeding (HR 0.61, 95% CI 0.38-0.96). OAC discontinuation >1 year post-AF ablation in patients with CHA2DS2-VA 2-4 was associated with lower composite stroke/embolism and major bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: